• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Patrick Soon-Shiong awarded Special Recognition Award

Patrick Soon-Shiong awarded Special Recognition Award

March 6, 2017
CenterWatch Staff

Patrick Soon-Shiong, M.D., CEO and founder of NantHealth, has been awarded the Intelligent Health Association (IHA) Special Recognition Award. The award recognizes his leadership in the healthcare technology community and his commitment to transforming cancer care through personalized medicine and combination immunotherapy.

The IHA annual awards identify and recognize the most compelling healthcare projects incorporating wireless technologies resulting in sustainable impact on the patient experience, safety and healthcare facility operations.

Criteria for the award is largely based on significant lifetime achievements in healthcare. As a surgeon, scientist and philanthropist, Dr. Soon-Shiong has dedicated his medical and scientific career to combating life-threatening diseases such as diabetes and cancer. Today, he is leading a collaboration of biotechnology and healthcare leaders on an unprecedented mission to treat cancer with next-generation novel immunotherapies. Earlier in his career, he performed the world's first encapsulated human islet cell transplant in several type I diabetic patients and continued his quest to develop groundbreaking treatments for cancer. Dr. Soon-Shiong invented Abraxane, the nation's first biologically active chemotherapy. The albumin-bound nanoparticle of paclitaxel is designed to enter the tumors micro-environment, which is approved today for the treatment of breast, lung and pancreatic cancer.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

  • SurveywBlueBackground-360x240.png

    Mid-Study Updates Delay Trials At Least a Month, CSDD Report Finds

  • Real-TimeData-360x240.png

    Real-Time Data Helped Sponsors Respond to Sites’ Needs During the Pandemic

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing